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Abstract
We have previously identified a shift from TNF-α-induced apoptosis to necroptosis that occurs under hyperglycemic
conditions. This shift involves the downregulation or silencing of caspases and concurrent upregulation of necroptotic
proteins leading to activation of the necrosome. In addition, under hyperglycemic conditions in vivo, this shift in cell
death mechanisms exacerbates neonatal hypoxia-ischemia (HI) brain injury. Here, we identify two major factors that
drive the hyperglycemic shift to necroptosis: (1) reactive oxygen species (ROS) and (2) receptor-interacting protein
kinase 1 (RIP1). ROS, including mitochondrial superoxide, led to the oxidation of RIP1, as well as formation and
activation of the necrosome. Concurrently, ROS mediate a decrease in the levels and activation of executioner
caspases-3, -6, and -7. Importantly, hyperglycemia and mitochondrial ROS result in the oxidation of RIP1 and loss of
executioner caspases prior to death receptor engagement by TNF-α. Moreover, RIP1 partially controlled levels of
mitochondrial ROS in the context of hyperglycemia. As a result of its regulation of ROS, RIP1 also regulated necrosome
activation and caspase loss. Mitochondrial ROS exacerbated neonatal HI-brain injury in hyperglycemic mice, as a result
of the shift from apoptosis to necroptosis.
Introduction
Necroptosis is the major pathway of programmed
necrosis and has been documented to occur in diverse cell
types, including erythrocytes, leukocytes, cardiac cells,
and neurons1–7. This pathway is driven by the cytosolic
necrosome complex, which consists of receptor-
interacting protein kinase 1 (RIP1), RIP3, and mixed
lineage kinase domain-like (MLKL) protein1,8,9. Down-
stream of this complex, MLKL oligomerizes and translo-
cates to the cell membrane, forming pores10–13. In
addition to MLKL, reactive oxygen species (ROS) are
major effectors in necroptosis8,14,15. The formation of
ROS during necroptosis is due to the interaction of
necrosome components with several metabolic factors in
the cell16. RIP3 may stimulate glycolysis and glutamate
metabolism via activation of glycogen phosphorylase and
glutamate ammonia ligase, respectively17. Moreover,
RIP3 stimulates the citric acid cycle via activation of
pyruvate dehydrogenase complex and glutamate dehy-
drogenase 1 (refs. 17,18). Stimulation at each of these
metabolic steps ultimately leads to increased respiratory
chain activity and ROS formation16. In addition, RIP1 has
been shown to have a key role in direct stimulation of
respiratory chain activity via activation of the transcrip-
tional coactivator, peroxisome proliferator-activated
receptor-gamma coactivator 1 alpha19. While ROS pro-
duce downstream cellular damage in necroptosis14,15, they
have recently been shown to be critical for the oxidation
and phosphorylation/activation of RIP1, inducing
necroptosis and amplifying it through a feedback
mechanism20.
In contrast to apoptosis, necroptosis results in a pro-
inflammatory outcome21–24. Rather than removal of dying
cells by macrophages, as is the case in apoptosis25, cells
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undergoing necroptosis lose membrane integrity and lyse,
releasing all cellular contents1,8,21. Despite the vast dif-
ferences in outcomes, there is some overlap in the initial
steps of TNF-induced apoptosis and necroptosis1,8,25.
Both pathways may be induced by TNF-α and involve the
formation of membrane–proximal protein complexes26–28.
Following this the signaling pathways diverge, with
apoptosis driven by caspases and complex II and
necroptosis driven by RIP1, RIP3, MLKL, and the
necrosome1,8,25. That these pathways share induction
steps and reach a point of divergence suggests that dif-
ferent cellular situations may favor one pathway over
the other.
We previously reported that hyperglycemia/high-glu-
cose conditions are a cellular situation that favors
necroptosis over apoptosis29. That work demonstrated
that high glucose potentiates a shift to RIP1-dependent
necroptosis, despite specific stimulation of extrinsic
apoptosis. In addition, we showed that this cell death shift
is relevant to neonatal hypoxia-ischemia (HI)-brain injury
in hyperglycemic mice29. At that time, we noted two
factors on which this cell death shift depended: RIP1 and
ROS29. In the current study, we aim to understand the
underlying molecular mechanism of the hyperglycemic
shift from apoptosis to necroptosis, with a primary focus
on the role of RIP1 and ROS. We demonstrate that ROS
are necessary and sufficient to produce the cell death shift
from apoptosis to necroptosis. Furthermore, we show that
ROS are partially dependent on RIP1 during the hyper-
glycemic shift to necroptosis. Importantly, ROS are also
necessary for this cell death shift in vivo, as we show an
exacerbation of neonatal HI-brain injury in
hyperglycemic mice.
Results
The hyperglycemic shift from apoptosis to necroptosis
depends on mitochondrial ROS
The hyperglycemic shift from apoptosis to necroptosis
involves ROS29. We measured total cellular levels of
oxidative stress, as well as mitochondrial ROS using
CellROX Green and MitoSOX Red, respectively. For this,
U937 cells were cultured in 10 or 50mM glucose at 37 °C
for 24 h, followed by the treatment with TNF-α/CHX for
6 h, staining, and flow cytometry. Both total cellular oxi-
dative stress and mitochondrial ROS exhibited a robust
increase in 50mM glucose (Fig. 1A, B). Through the use
of specific inhibitors, we probed the source of cellular
ROS during this cell death shift. U937 monocytes were
cultured in 10 or 50mM glucose at 37 °C for 24 h followed
by the treatment with TNF-α/CHX for 24 h in the pre-
sence or absence of various inhibitors. In line with our
previous work, TNF-α/CHX-induced cell death increased
in 50mM glucose (Fig. 1C–F). Scavenging of mitochon-
drial ROS with mitoTEMPO30,31 prevented this increase
in cell death (Fig. 1C). Scavenging of cellular hydrogen
peroxide with catalase32,33, however, had no effect on cell
Fig. 1 The hyperglycemic shift to necroptosis depends on mitochondrial ROS. U937 cells were grown in 10 or 50 mM glucose followed by the
treatment with TNF-α/CHX for 4 h. Cells were then stained with A CellROX Green or B MitoSOX Red, and analyzed by flow cytometry. There is a
robust increase in staining for both reagents in cells treated with TNF-α/CHX in 50 mM glucose. U937 cells were grown in 10 or 50 mM glucose
followed by the treatment with TNF-α/CHX for 24 h in the presence of vehicle controls or C mitochondrial ROS scavenger, mitoTEMPO, D catalase,
and E NADPH oxidase inhibitor, VAS-2870. WST-1 viability assays revealed that cell death in 50 mM glucose was prevented by mitoTEMPO and none
of the other inhibitors. All results are from three independent experiments. Graphed values represent mean ± standard deviation. Two-way ANOVA,
***p < 0.001.
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death in 50mM glucose (Fig. 1D). In addition, inhibition
of NADPH oxidases, another source of ROS34, with VAS-
2870 did not affect cell death in 50 mM glucose (Fig. 1E).
These results suggest that mitochondrial ROS are the
source that drives the hyperglycemic shift from apoptosis
to necroptosis.
ROS and RIP1 regulate one another during the
hyperglycemic shift to necroptosis
We previously established that RIP1 is a key factor in
the hyperglycemic shift from apoptosis to necroptosis29.
When the RIP1 gene is deleted in U937 monocytes they
undergo caspase-dependent apoptosis in response to
TNF-α/CHX under hyperglycemic conditions29. To probe
the role of RIP1 further, we utilized a U937 cell line in
which RIP1 was deleted using CRISPR-Cas9 (ref. 29), as
well as U937 cells transfected with nonspecific guide RNA
as a nontargeting control (NTC). These cells were grown
in 10 or 50 mM glucose at 37 °C for 24 h, followed by the
treatment with TNF-α/CHX for 6 h at 37 °C. Using
mitoSOX Red and flow cytometry, we measured levels of
mitochondrial ROS. MitoSOX Red staining increased by
approximately fourfold in NTC cells in 50mM glucose
(Fig. 2A). However, rip1 CRISPR KO cells only exhibited
approximately twofold increase in mitoSOX staining in
50mM glucose (Fig. 2A). This indicates that RIP1
Fig. 2 RIP1 and mitochondrial ROS act on one another during the hyperglycemic shift to necroptosis. A rip1 CRISPR KO U937 cells or those
transfected with nontargeting control guide RNA (NTC) were grown in 10 or 50 mM glucose, treated with TNF-α/CHX for 4 h followed by staining
with MitoSOX Red and flow cytometry. The robust increase in MitoSOX Red staining in NTC cells in 50 mM glucose is blunted in rip1 CRISPR KO cells.
Results are from three independent experiments. Graphed values represent mean ± standard deviation. Two-way ANOVA, ***p < 0.001. B rip1 CRISPR
KO or NTC cells were grown in 10 or 50 mM glucose, treated with TNF-α/CHX for 2.5 h followed by lysate preparation and immunoblotting. Caspases-
3, -6, and -7 decrease in NTC cells in 50 mM glucose, however, this decrease is not exhibited in rip1 CRISPR KO cells. C rip1 CRISPR KO or NTC cells
were treated as in B followed by immunoprecipitation of RIP3 and immunoblotting. RIP3 is phosphorylated (p-RIP3) and MLKL co-precipitates in NTC
cells in 50 mM glucose. Phosphorylation of RIP3 and co-precipitation of MLKL with RIP3 was not exhibited in rip1 CRISPR KO cells. WT U937 cells were
treated as in B in the presence or absence of D antioxidant, N-acetylcysteine (NAC) or E superoxide dismutase inhibitor, diethyldithiocarbamate
(DDC). Total RIP1 levels were normalized. Phosphorylation of RIP1 (p-RIP1) is exhibited in 50 mM glucose and prevented by NAC. Treatment with DDC
led to p-RIP1 in 10 or 50 mM glucose. All western blot images are representative of three independent experiments.
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partially regulates the increase in mitochondrial ROS
during the hyperglycemic shift to necroptosis. In a sepa-
rate set of experiments, the rip1 CRISPR KO or NTC cells
were grown in 10 or 50 mM glucose at 37 °C for 24 h,
followed by the treatment with TNF-α/CHX for 2.5 h at
37 °C, lysate preparation, and western blotting. Total and
activated levels of executioner caspases-3, -6, and -7
decrease in NTC cells in 50mM glucose (Fig. 2B). This
decrease did not occur in rip1 CRISPR KO cells in 50mM
glucose (Fig. 2B). This shows that RIP1 is needed for the
decrease in levels and activation of caspases during the
hyperglycemic shift to necroptosis. In a similar set of
experiments, RIP3 was immunoprecipitated and analyzed
by western blot. RIP3 phosphorylation and co-
precipitation of MLKL with RIP3 both increased in
NTC cells in 50mM glucose (Fig. 2C). However, this
increase did not occur in rip1 CRISPR KO cells in 50mM
glucose (Fig. 2C). This indicates that RIP1 is necessary for
RIP3 phosphorylation and necrosome formation during
the hyperglycemic shift to necroptosis. Interestingly, while
RIP1 appears to regulate mitochondrial ROS during the
hyperglycemic shift to necroptosis (Fig. 2A), ROS
scavenging by N-acetylcysteine (NAC) resulted in a
decrease in total and phosphorylated RIP1 in 50mM
glucose (Fig. 2D and Fig. S1A). Moreover, induction of
ROS with the superoxide dismutase inhibitor, diethyl-
dithiocarbamate (DDC), resulted in increased total levels
and phosphorylation of RIP1, even in 10mM glucose
conditions (Fig. 2E and Fig. S1B). Collectively, these
results indicate that while RIP1 regulates mitochondrial
ROS during the hyperglycemic shift to necroptosis, it is
reciprocally regulated by ROS.
Reactive oxygen species activate necroptosis kinases while
inhibiting caspases
RIP1 is known to be oxidized by ROS, causing it to form
a high MW oligomer necessary for its autopho-
sphorylation20. To investigate if this occurs during the
hyperglycemic shift to necroptosis, U937 monocytes were
cultured in 10 or 50mM glucose at 37 °C for 24 h, fol-
lowed by the treatment with TNF-α/CHX in the presence
or absence of NAC. Analysis of lysates separated by
nonreducing SDS–PAGE and detected by western blot
revealed the presence of oxidized RIP1 in 50 mM glucose
conditions (Fig. 3A). This high MW RIP1 oligomer was
inhibited by NAC in 50mM glucose (Fig. 3A). Using
conventional SDS–PAGE and western blot, we deter-
mined that total and phosphorylated levels of RIP3 and
MLKL increased in 50mM glucose conditions (Fig. 3B
and Fig. S1A). The increase in total levels and phos-
phorylation, however, was prevented by the inhibition of
ROS with NAC (Fig. 3B and Fig. S1A). Immunoprecipi-
tation of RIP1 revealed that co-precipitation of RIP3 and
MLKL in 50mM glucose was prevented by NAC (Fig. 3C).
Conversely, levels of executioner caspases-3, -6, and -7
decreased in 50mM glucose, but rebounded upon ROS
scavenging with NAC (Fig. 3D). These results suggest a
key role for ROS in silencing apoptosis, while activating
necroptosis in high-glucose conditions.
To probe the role of ROS further, we utilized the
superoxide dismutase inhibitor, DDC, to induce ROS
independent of cellular glucose levels (Fig. 4A). For this,
U937 cells were cultured in 10 or 50mM glucose for 24 h
at 37 °C, followed by the treatment with TNF-α/CHX in
the presence or absence of DDC. Analysis of lysates via
nonreducing SDS–PAGE and western blot showed RIP1
oxidation in DDC-treated samples, regardless of the pre-
sence of 10 or 50mM glucose (Fig. 4B). In addition, total
levels and phosphorylation of RIP3 and MLKL increased
following DDC treatment in 10 or 50mM glucose (Fig. 4C
and Fig. S1B). Immunoprecipitation of RIP1 showed that
co-precipitation of RIP3 and MLKL occurred following
DDC treatment in 10 or 50mM glucose (Fig. 4D). More-
over, total and activated levels of executioner caspases-3,
-6, and -7 decreased following treatment with DDC
(Fig. 4E). Taken together, these results suggest and activity.
Reactive oxygen species are necessary and sufficient to
produce the shift from apoptosis to necroptosis
Our results thus far suggest a central role for ROS in
promoting the hyperglycemic shift from apoptosis to
necroptosis. To determine if ROS can promote this cell
death shift independent of increased cellular glucose,
U937 cells were cultured in 10mM glucose for 24 h at
37 °C, followed by the treatment with TNF-α/CHX in the
presence or absence of DDC. Cell viability was then
measured and the impact of the RIP1 inhibitor,
necrostatin-1s (nec-1s), and pan-caspase inhibitor, zVAD-
fmk, was assessed. Treatment of U937 cells with TNF-α/
CHX in the absence of DDC resulted in cell death that
was prevented by zVAD-fmk (Fig. 5A). This is expected as
TNF-α/CHX is a stimulus of apoptosis in normal glucose
conditions25. Upon treatment with DDC, total cell death
increased and could no longer be inhibited by zVAD-fmk
(Fig. 5A). Conversely, the increased cell death seen in
DDC conditions was prevented by nec-1s (Fig. 5B). These
results indicate that cellular ROS are necessary and suf-
ficient for the shift from apoptosis to necroptosis.
Hyperglycemia primes the shift to necroptosis via ROS-
induced activation of RIP1 and caspase loss prior to death
receptor engagement
Having established a role for ROS in promoting the
hyperglycemic shift to necroptosis, we next determined
the effect of high glucose on ROS production in the
absence of death receptor stimulation by TNF-α/CHX.
U937 cells were cultured in 10 or 50 mM glucose for 24 h,
followed by the treatment with DDC for 2.5 h, staining
Deragon et al. Cell Death Discovery           (2020) 6:132 Page 4 of 12
Official journal of the Cell Death Differentiation Association
with CellRox or MitoSOX reagents and flow cytometry.
Even in the absence of TNF-α/CHX, there were robust
increases in oxidative stress and mitochondrial ROS in
50mM glucose or following treatment with DDC (Fig. 6A,
B). As we observed increases in ROS in hyperglycemic
conditions in the absence of TNF-α/CHX, we asked about
the oxidation state of RIP1 in this situation. Indeed, RIP1
was oxidized to a high MW species in 50mM glucose or
following DDC treatment in the absence of stimulation by
TNF-α/CHX (Fig. 6C). Moreover, levels of caspases-3, -6,
and -7 decreased in 50 mM glucose or following DDC
treatment in the absence of stimulation by TNF-α/CHX
(Fig. 6D). Collectively, these results suggest that hyper-
glycemia primes cells for the shift from apoptosis to
necroptosis via ROS-induced activation of RIP1 and loss
of caspases.
The hyperglycemic shift from apoptosis to necroptosis
exacerbates neonatal HI-brain injury via mitochondrial
ROS
We have previously shown that the hyperglycemic shift
from apoptosis to necroptosis occurs in hyperglycemic
mice during neonatal HI-brain injury5,29. To determine
the role of ROS in this cell death shift in vivo, we first
detected oxidized RIP1 in brain homogenates. This high
MW species of RIP1 increased in hyperglycemic mice
undergoing neonatal HI-brain injury (Fig. 7A). Next, we
determined the impact of mitochondria-targeted S-
nitrosothiol (mitoSNO) on neonatal HI-brain injury in
hyperglycemic mice. MitoSNO is a deactivator of mito-
chondrial complex I and thus ROS production35. Pre-
viously, it was shown that mitoSNO decreased ROS and
prevented oxidative damage during neonatal HI-brain
injury in normal mice36. Here, we show that administra-
tion of mitoSNO prevents exacerbation of infarct size
seen in hyperglycemic mice undergoing neonatal HI-brain
injury (Fig. 7B, C). Lysates from brain homogenates were
analyzed via western blot, revealing an increase in total
RIP1 in hyperglycemic mice that was prevented by
mitoSNO (Fig. 7D). As seen previously, executioner cas-
pases-3, -6, and -7 decreased in hyperglycemic mice
undergoing neonatal HI-brain injury29. Administration of
mitoSNO prevented this loss in caspases (Fig. 7D). In
addition, PARP1 cleavage, a marker of apoptosis25,
Fig. 3 Activation of necrosome components and deactivation/loss of executioner caspases is driven by ROS in high-glucose conditions.
A U937 cells were grown in 10 or 50 mM glucose followed by the treatment with TNF-α/CHX in the presence or absence of antioxidant, N-
acetylcysteine (NAC), for 2.5 h followed by nonreducing SDS–PAGE and immunoblotting. A high MW, oxidized form of RIP1 is exhibited in 50 mM
glucose, but is prevented by NAC. B U937 cells were treated as in A followed by reducing SDS–PAGE and immunoblotting. Total levels of RIP3 and
MLKL were normalized. RIP3 and MLKL phosphorylation (p-RIP3 and p-MLKL, respectively) occurs in 50 mM glucose and is prevented by NAC. C U937
cells were treated as in A followed by immunoprecipitation of RIP1, reducing SDS–PAGE, and immunoblotting. RIP3 and MLKL co-precipitate with
RIP1 in 50 mM glucose, but this is prevented by NAC. D U937 cells were treated as in B. Caspases-3, -6, and, -7 exhibit a decrease in activation and
abundance in 50 mM that is prevented by NAC. All western blot images are representative of three independent experiments.
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Fig. 4 Glucose-independent induction of ROS causes the activation of necrosome components and deactivation/loss of executioner
caspases. A U937 cells were grown in 10 or 50 mM glucose followed by the treatment with TNF-α/CHX in the presence or absence of superoxide
dismutase inhibitor, diethyldithiocarbamate (DDC), for 4 h. Cells were then stained with MitoSOX Red and analyzed by flow cytometry. Glucose-
independent induction of ROS with DDC produces a fold increase in MitoSOX staining similar to that exhibited in 50 mM glucose. Results are from
three independent experiments. Graphed values represent mean ± standard deviation. Two-way ANOVA, ***p < 0.001. B U937 cells were grown in 10
or 50 mM glucose followed by the treatment with TNF-α/CHX in the presence or absence of DDC for 2.5 h followed by nonreducing SDS–PAGE and
immunoblotting. RIP1 exists as a high MW, oxidized species in 50 mM glucose as well as in 10 or 50 mM glucose+ DDC. C U937 cells were treated as
in B followed by reducing SDS–PAGE and immunoblotting. Total levels of RIP3 and MLKL were normalized. RIP3 and MLKL are phosphorylated
(p-RIP3 and p-MLKL, respectively) in 50 mM glucose and 10 or 50 mM glucose+ DDC. D U937 cells were treated as in B followed by
immunoprecipitation of RIP1, reducing SDS–PAGE, and immunoblotting. Both RIP3 and MLKL co-precipitate with RIP1 in 50 mM glucose and 10 or
50 mM glucose+ DDC. E U937 cells were treated as in C. Caspases-3, -6, and -7 decrease in activation and abundance in 50 mM glucose and 10 or
50 mM glucose+ DDC. All western blot images are representative of three independent experiments.
Deragon et al. Cell Death Discovery           (2020) 6:132 Page 6 of 12
Official journal of the Cell Death Differentiation Association
decreased in hyperglycemic mice, but rebounded upon
mitoSNO treatment (Fig. 7D). When RIP1 was immu-
noprecipitated from hyperglycemic brain homogenates,
RIP3 and MLKL co-precipitated, indicating necrosome
formation (Fig. 7E). This co-precipitation was prevented
following mitoSNO treatment (Fig. 7E). In agreement
with this, RIP1 phosphorylation increased in hypergly-
cemic mice and was prevented by mitoSNO (Fig. 7E).
Collectively, these results indicate that the hyperglycemic
shift from apoptosis to necroptosis, which exacerbates
neonatal HI-brain injury, depends on ROS (Fig. 8).
Discussion
ROS as regulators of cell death signaling
This work identifies ROS as important regulators of
necroptosis, consistent with previous reports14,20. How-
ever, in this study, we have identified ROS as factors that
regulate a switch from apoptosis to necroptosis. This
Fig. 6 High glucose and ROS primes cells to undergo necroptosis, while preventing apoptosis in the absence of death receptor ligands.
U937 cells were grown in 10 or 50 mM glucose in the presence or absence of superoxide dismutase inhibitor, diethyldithiocarbamate (DDC), for 24 h.
Cells were then stained with A Cellrox Green or B MitoSOX Red, and analyzed by flow cytometry. There is a robust increase in staining for both
reagents in cells grown in 50 mM glucose or those treated with DDC in normal glucose. Results in A and B are from three independent experiments.
Graphed values represent mean ± standard deviation. Two-way ANOVA, ***p < 0.001. C U937 cells were grown in the presence or absence of DDC for
24 h followed by immunoblotting. RIP1 exists as a high MW, oxidized species in cells grown in 50 mM glucose or those treated with DDC. D U937
cells were treated as in C. Caspases-3, -6, and -7 decrease in cells grown in 50 mM glucose or treated with DDC. These results indicate that high
glucose or ROS predispose cells to undergo necroptosis in the absence of TNF-α or other death receptor ligands. All western blot images are
representative of three independent experiments.
Fig. 5 Glucose-independent induction of ROS produces a shift
from apoptosis to necroptosis. U937 cells were grown in 10 mM
glucose and treated with TNF-α/CHX in the presence or absence of
superoxide dismutase inhibitor, diethyldithiocarbamate (DDC), for 24 h
followed by WST-1 viability assay. A Cell death in the absence of DDC
is prevented by the pan-caspase inhibitor, zVAD-fmk. Cell death in the
presence of DDC is unaffected by zVAD-fmk. B Cell death in the
presence of DDC is prevented by RIP1 inhibitor, necrostatin-1s (nec-
1s). All results are from three independent experiments. Graphed
values represent mean ± standard deviation. Two-way ANOVA, ***p <
0.001.
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occurs in a particular scenario: a hyperglycemic environ-
ment. TNF-induced apoptosis and necroptosis overlap in
the first several steps of their signaling followed by a
divergence of both pathways1,8,9,25. What regulates that
divergence has been a topic of ongoing research. In the
TNF-α pathways of apoptosis and necroptosis, this point
of divergence is the formation of cytoplasmic complex II.
It is at this step that either caspase-8 or RIP1 become
activated depending upon whether apoptosis or necrop-
tosis is occurring, respectively1,8,9,25. The formation of
Fig. 7 The hyperglycemic shift to necroptosis is driven by mitochondrial ROS during neonatal hypoxia-ischemia brain injury. Normal
or hyperglycemic neonatal (p10) C57BL/6 mice were subjected to regional cerebral hypoxia-ischemia and sacrificed at 24 h of reperfusion.
A Nonreducing SDS–PAGE and immunoblot of contralateral (cn) and ipsilateral (ip) tissue. There is a robust increase in the high MW, oxidized species
of RIP1 in ipsilateral tissue from hyperglycemic mice. B Isolated brain tissue was stained with triphenly-tetrazolium (TTC) to measure infarct volume.
Infarct volume is increased in hyperglycemic mice but is prevented by mitochondrial complex I deactivator, mitoSNO. N= 7 per mouse group.
Graphed values represent mean ± standard deviation. One-way ANOVA with Fisher’s post hoc. C Representative images corresponding to
quantitative results shown in B. D Reducing SDS–PAGE of contralateral and ipsilateral tissue. RIP1 increases while apoptotic markers, caspases-3, -6, -7,
and PARP1 cleavage decrease in hyperglycemic mice. These trends are reversed by mitoSNO. E Immunoprecipitation of RIP1 from brain tissue. RIP1 is
phosphorylated (p-RIP1) and RIP3 and MLKL co-precipitate with RIP1 in hyperglycemic mice. This did not occur in hyperglycemic mice treated with
mitoSNO.
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increased ROS as a result of exposure to high glucose is a
key factor, which causes signaling to proceed in favor of
necroptosis at this point of divergence. This hypergly-
cemic shift from apoptosis to necroptosis requires RIP1 in
addition to ROS as this shift does not occur in its absence
(Fig. 2B, C)29. While we have previously reported that
high glucose leads to a shift from apoptosis to necropto-
sis5,29, the underlying mechanism remained unclear.
Thus, this work reveals the roles of RIP1 and ROS in the
mechanism of the hyperglycemic shift to necroptosis.
Mechanism of the hyperglycemic shift from apoptosis to
necroptosis
Identifying ROS and RIP1 as key factors in the hyper-
glycemic shift from apoptosis to necroptosis has allowed
us to determine a model mechanism. In the presence of
normal glucose, engagement of the TNF receptor (TNFR)
by TNF-α leads to the activation of caspase-8 and
downstream executioner caspases causing apoptosis25. In
the presence of high glucose, mitochondrial ROS produce
a shift from apoptosis to necroptosis by mediating the
following molecular changes: (1) oxidization of RIP1
leading to formation of a high MW oligomer, (2)
formation of the necrosome leading to phosphorylation of
RIP1, RIP3, and MLKL, and (3) decrease in the levels and
activation of executioner caspases-3, -6, and -7. As a result
of these molecular changes, apoptosis is silenced and
necroptosis ensues in its place. In addition, our work has
revealed that oxidation of RIP1 and loss of executioner
caspases occurs in response to high glucose in the absence
of death receptor engagement (Fig. 6). This suggests that
ROS prime hyperglycemic cells to undergo necroptosis
once they are bound by TNF-α.
Previous publications have shown that oxidized RIP1 is
sometimes associated with a shadowing between mono-
meric RIP1 and oxidized RIP1 (>300 kDa) on western
blots20. Despite this shadowing, those publications iden-
tified a >300 kDa band at the top of the gel as oxidized
RIP1 (ref. 20). Following their approach, we also identify a
>300 kDa band as oxidized RIP1. We feel confident that
the identity of this band is oxidized RIP1. We believe this
as this high MW species was abolished by an antioxidant
(Fig. 3A) and induced by ROS via inhibition of superoxide
dismutases (Fig. 4B). The shadowing effect above mono-
meric RIP1 has also been observed on reducing western
blots37, suggesting it may be artefactual.
Fig. 8 Model mechanism of the ROS-induced shift from apoptosis to necroptosis. In a hyperglycemic environment, high levels of cellular
glucose lead to the production of mitochondrial ROS. Increased cellular ROS results in a decrease in the levels of executioner caspases with a
concurrent increase in RIP1, RIP3, and MLKL, while also oxidizing RIP1 to a high MW oligomer. Once TNF-α engages TNFR, ROS promote formation of
the necrosome and activation of RIP1, RIP3, and MLKL, while inhibiting activation of executioner caspases. In effect, the increased ROS silence
apoptosis, while promoting necroptosis.
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Translational relevance
This ROS-driven shift from apoptosis to necroptosis
exacerbates neonatal HI-brain injury in the context of
hyperglycemia (Fig. 7). In our experiments, we used
mitoSNO35 which limits superoxide generation in the
mitochondrial respiratory chain during reperfusion36. As
mitoSNO protected against the hyperglycemia-driven
exacerbation of neonatal HI-brain injury, this suggests a
key role for mitochondrial ROS in this phenomenon.
Moreover, our data suggests that ROS of mitochondrial
origin mediate a shift from apoptosis to necroptosis during
hyperglycemia (Fig. 7D, E). While the exact mechanisms for
hyperglycemia-elevated ROS production in mitochondria is
yet to be determined, it has been shown that during cano-
nical necroptosis RIP1, RIP3, and MLKL translocate to the
mitochondria and stimulate ROS production38. From an
in vivo perspective, cerebral ischemia is associated with a
dramatic increase in succinate accumulation36,38. Upon
reperfusion, this accumulated succinate leads to excessive
ROS release in mitochondrial complex I via reverse electron
transfer38. MitoSNO transiently inhibits complex I reacti-
vation during reperfusion and, therefore, significantly limits
reverse electron transfer and the rate of superoxide pro-
duction35,36. This suggests a possible role for reverse elec-




U937 monocytes were obtained from ATCC (Manassas,
VA, USA) and were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum at 37 °C and
5% CO2. rip1 CRISPR KO and NTC U937 cell lines were
generated using the CRISPR-Cas9 lentiviral system, as
previously described29. NTC and rip1 CRISPR KO cells
were cultured with 3 µg/mL puromycin for selection
under the same conditions as the U937 wild-type cells. All
cell lines have been recently authenticated and are free of
Mycoplasma contamination.
Inhibitors and ROS scavengers
Pharmacological inhibitors were incubated with the
cells at 37 °C and 5% CO2 for 1 h prior to the addition of
TNF-α at the following concentrations: VAS-2870 (5 μM),
CCCP (10 μM), DDC (1 μM), nec-1s (50 μM), and zVAD-
fmk (50 μM). ROS scavengers were similarly incubated
prior to the addition of TNF-α at the following con-
centrations: catalase (100 units/mL), NAC (10mM) and
mitoTEMPO (500 μM). All inhibitors and ROS sca-
vengers were purchased from Millipore-Sigma.
Preparation of cell lysates
U937 wildtype, NTC, and rip1 CRISPR KO cells were
cultured in media supplemented with 10 or 50mM
glucose for 24 h at 37 °C and 5% CO2. Following this, they
were treated with 1 ng/mL TNF-α and 0.25 µg/mL
cycloheximide for 2.5 h. Cells were washed with PBS and
lysed with Tris-buffered saline (TBS) supplemented with
1% triton X-100, 1 mM phenylmethylsulfonyl fluoride,
1 mM sodium orthovanadate, and 1× ProBlock™ Gold
(Goldbio) for 30 min on ice. Lysates were clarified by
centrifugation at 20,000 × g for 20 min at 4 °C. For some
experiments, cells were cultured in 10 or 50mM glucose
for 24 h followed by lysate preparation. For other
experiments, cells were cultured in 10 or 50mM glucose
for 24 h followed by the treatment with DDC for 2.5 h and
lysate preparation. All reagents were obtained from
Millipore-Sigma unless indicated otherwise.
Immunoprecipitations
Immunoprecipitation of RIP1 or RIP3 was performed
on U937, rip1 CRISPR KO, or NTC cell lysates prepared,
as detailed above. Following lysate creation, supernatants
were precleared with agarose beads, and incubated with
10 µg of anti-human RIP1 (BD Biosciences) or RIP3 (Cell
Signaling Technology) added to supernatants and allowed
to incubate with gentle mixing overnight at 4 °C. Super-
natants were then incubated with Protein G Plus agarose
beads (Pierce) for 2 h at room temperature. Beads were
washed thoroughly, resuspended in 1× Laemmli buffer,
run on SDS–PAGE, and western blotted.
Cell death assays
Cells were incubated for 24 h in RPMI 1640 media
containing 10 or 50mM glucose at 37 °C and 5% CO2.
Cells were adjusted to 1 × 106 cells/mL in fresh media and
treated with 0.4 lytic units of TNF-α and 0.25 µg/mL
cycloheximide for 24 h. The lytic units of TNF-α have
been described previously29. Pharmacological inhibitors
and ROS scavengers were added where indicated at the
concentrations listed above. For each WST-1 assay n= 6.
This n was chosen based on previous experiments5,29.
WST-1 assays were performed in three independent
experiments. WST-1 reagent was used to measure cell
death according to the manufacturer’s instructions
(Takara). Using WST-1, percent viability was calculated as
follows:
%Viability ¼ 100 ´ absorbance of TNFα=CHX treated cells
absorbance of negative control cells
:
Flow cytometry (CellROX and MitoSOX)
For flow cytometry analyses, 10,000 events were col-
lected for each sample after gating out debris. Sample data
were collected utilizing a BD FACSVerse flow cytometer.
Data files were analyzed using FlowJo V10. Prior to ana-
lysis, cells (U937, rip1 CRISPR KO, and NTC) were
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incubated in 10 or 50 mM glucose for 24 h at 37 °C and
5% CO2. Cells were treated with 1 ng/mL TNF-α at 37°C
and 5% CO2 for 4 h. For ROS detection, CellROX Green
reagent or MitoSOX Red superoxide indicator (Invi-
trogen) were added to cells at a final concentration of
5 μM and used according to the manufacturer’s
instructions. For some experiments, cells were cultured
in 10 or 50 mM glucose for 24 h followed by staining and
flow cytometry. For other experiments, cells were cul-
tured in 10 or 50 mM glucose for 24 h followed by the
treatment with DDC for 4 h, and staining and flow
cytometry. For each flow cytometry experiment n= 6.
This n was chosen based on previous experiments29.
Flow cytometry experiments were performed in three
independent experiments.
Western blots
Lysates, immunoprecipitates, and tissue homogenates
were separated via SDS–PAGE, with and without the
inclusion of reducer (2-mercaptoethanol), transferred to a
PVDF membrane, and blocked in TBS-T buffer contain-
ing either 5% milk or BSA (for phosphorylated proteins)
for 30min at room temperature. The blots were incubated
with primary antibody diluted in block buffer overnight at
4 °C. All primary antibodies were obtained from Cell
Signaling Technology, unless otherwise indicated. Pri-
mary antibodies were used at the following dilutions: anti-
human GAPDH (1:10000), anti-human caspase-3
(1:1000), anti-human/mouse caspase-6 (1:1000), anti-
human/mouse caspase-7 (1:1000), anti-human RIP1
(1:1000), anti-human p-RIP1 (1:1000), anti-human RIP3
(LSBio, 1:1000), anti-human p-RIP3 (1:1000), anti-human
MLKL (1:1000), anti-human p-MLKL (1:1000), anti-
mouse β-tubulin (1:1000), anti-mouse caspase-3
(1:1000), anti-mouse caspase-6 (1:1000), anti-mouse cas-
pase-7 (1:1000), anti-mouse PARP1 (1:1000),anti-mouse
RIP1 (1:1000), anti-mouse p-RIP1 (1:1000), anti-mouse
RIP3 (1:1000), and anti-mouse MLKL (1:1000). Following
overnight incubation, blots were washed with TBS-T
containing 5% milk (or BSA), incubated with secondary
HRP conjugate antibodies for 1 h at room temperature.
After the final wash, blots were developed with chemilu-
minescent substrate and read in a Bio-Rad ChemiDoc
XRS+. All western blots are the results of three inde-
pendent experiments.
In vivo brain hypoxia-ischemia model
All studies were conducted according to a protocol
approved by the Columbia University Institutional Ani-
mal Care and Use Committee and in accordance with the
Association for Assessment and Accreditation of
Laboratory Animal Care guidelines. Hyperglycemia was
induced in male and female neonatal (p10) C57BL/6 J
mice subjected to regional HI-brain injury according to
our description in ref. 5. Immediately after HI, mice were
administered with either MitoSNO (500 ng/kg) or vehicle
(DMSO) intranasally, 1 μl aliquots (10 μl total), over
40min. At 24 h of reperfusion, all mice were sacrificed
and the extent of brain injury was estimated using
triphenly-tetrazolium (TTC) staining. Infarct volume was
expressed as % of the hemisphere ipsilateral to the carotid
artery ligation side. Brain tissue was also used to create
homogenates which were analyzed by immunoprecipita-
tion, SDS–PAGE, and western blot. N= 7 per mouse
group. This n was chosen based on power analysis and
previous experiments5. For TTC staining and analysis,
investigators were blinded (unaware of sample identity),
effectively randomizing the samples.
Statistical analysis
Two-way ANOVA with Bonferroni posttest was used to
analyze significance of all quantitative in vitro data. One-
way ANOVA test with Fisher’s post hoc analysis was used
to determine difference in cerebral infarct volume in vivo.
All results are from three or more independent experi-
ments. Statistics were calculated using GraphPad
Prism 5.0.
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